The advent of requiring multiple non-animal in vitro alternatives for skin sensitization assessments has prompted the Organisation for Economic Co-operation and Development (OECD) to publish new guidance to outline the approaches for data interpretation from multiple non-animal test methods. When used together in specific combinations, these methods will aid with …
iCAN focus group highlights need for youth representation in clinical trials
As the name would suggest, patient-centric clinical trials rely on the patient voice. This is especially true in pediatric therapies, where younger patients are engaged to share their unique insights on new investigational products but may be unfamiliar or uncomfortable with advanced clinical trial concepts. As a proud sponsor of …
Learn about the latest in Labcorp DCT solutions by connecting with us at regional meetings around the globe – May 2022
Welcome to the May 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. Because spring is a time traditionally packed with industry conferences, we will devote this blog to reviewing some of the highlights of our plans for the spring conference season. We hope to connect with you at one …
Application of decentralized clinical trials on AI-focused dermatology
Leveraging AI-focused dermatology in decentralized clinical trials The use of virtual tools and telecommunications skyrocketed during the COVID-19 pandemic as the world adjusted to new ways of working. In the clinical trials sector, this propelled an increasing adaptation to the decentralized clinical trial (DCT) approach to support research and minimize …
The evolution of Central Laboratory planning and forecasting to enable more efficient study delivery
Fostering trust with customers starts with delivering study materials on time, underscoring the importance of planning and forecasting processes to meet current demands. While the pandemic highlighted the need to adjust approaches and address the industry’s supply chain disruptions, it also brought forth enhanced planning and forecasting methods at Labcorp. …
NHS England’s Rare Disease Action Plan: Renewed focus on access to innovative drugs
In England, February 2022 has seen the lifting of all COVID-19 restrictions. As we cautiously enter a “new normal” after the disruption caused by the pandemic, there is renewed focus on previous healthcare priorities. The development and commercialization of innovative treatments for rare diseases has long been an area of …
Advancing inhalation toxicology capabilities to support chemical testing
Respiratory exposure to chemicals or agrochemicals poses potential risk to human health, especially to workers handling these products. Whether preparing a solution, dusting or spraying crops, or cleaning equipment, opportunities for inadvertent inhalation is a risk that can potentially lead to toxic effects, both acute and chronic. That’s why identifying …
Eight instrument considerations in flow cytometry
Whether it’s developing fit-for-purpose, customized flow assays, or optimizing the most appropriate off-the-shelf assay, the Labcorp Central Laboratory Services flow cytometry specialty testing team generates high-quality, clinically relevant and actionable data for your drug development programs. Here, we discuss how we choose our flow cytometry instruments to execute multi-site operations …
Detecting measurable residual disease (MRD) in hematological malignancies using flow cytometry
A patient may be in complete remission during or after a cancer treatment, but a few cancer cells may persist in what is known as residual disease. To better inform prognoses, understand treatment decisions, predict a patient’s overall survival or understand the potential for disease relapse, it is important to …
Identifying alternative supplies to address global supply chain issues and deliver custom clinical trial kits
Disruption across the global supply continues to challenge clinical trial operations, so the Labcorp Global Supply Chain Sourcing and Procurement team has leveraged Labcorp’s scale and expertise to reconfigure relationships with manufacturers and develop new processes for identifying and qualifying alternative supplies for customized clinical trial kits. This article shares …